

Alle Publikationen mit Autorschaft / Coautorschaft Ulrich Keller im SFB824:

1. Heider M, Eichner R, Stroh J, Morath V, Kuisl A, Zecha J, Lawatscheck J, Baek K, Garz AK, Rudelius M, Deuschle FC, Keller U, Lemeer S, Verbeek M, Götze KS, Skerra A, Weber WA, Buchner J, Schulman BA, Kuster B, Fernández-Sáiz V, Bassermann F. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. *Mol Cell*. 2021 Mar 18;81(6):1170-1186.e10. doi: 10.1016/j.molcel.2020.12.046. Epub 2021 Feb 10. PMID: 33571422; PMCID: PMC7980223.
2. Wirth M, Schick M, Keller U, Krönke J. Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. *Cancers (Basel)*. 2020 Dec 14;12(12):3764. doi: 10.3390/cancers12123764. PMID: 33327527; PMCID: PMC7764993.
3. Lankes K, Hassan Z, Doffo MJ, Schneeweis C, Lier S, Öllinger R, Rad R, Krämer OH, Keller U, Saur D, Reichert M, Schneider G, Wirth M. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. *Mol Oncol*. 2020 Dec;14(12):3048-3064. doi: 10.1002/1878-0261.12835. Epub 2020 Nov 8. PMID: 33099868; PMCID: PMC7718946.
4. Schneeweis C, Hassan Z, Schick M, Keller U, Schneider G. The SUMO pathway in pancreatic cancer: insights and inhibition. *Br J Cancer*. 2021 Feb;124(3):531-538. doi: 10.1038/s41416-020-01119-6. Epub 2020 Oct 19. PMID: 33071285; PMCID: PMC7851129.
5. Herhaus P, Lipkova J, Lammer F, Yakushev I, Vag T, Slotta-Huspenina J, Habringer S, Lapa C, Pukrop T, Hellwig D, Wiestler B, Buck AK, Deckert M, Wester HJ, Bassermann F, Schwaiger M, Weber W, Menze B, Keller U. CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. *J Nucl Med*. 2020 Dec;61(12):1765-1771. doi: 10.2967/jnumed.120.241703. Epub 2020 Apr 24. PMID: 32332145.
6. Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. *Gut*. 2020 Aug;69(8):1472-1482. doi: 10.1136/gutjnl-2018-317856. Epub 2020 Jan 30. PMID: 32001555; PMCID: PMC7398468.
7. O'Connor T, Zhou X, Kosla J, Adili A, Garcia Beccaria M, Kotsiliti E, Pfister D, Johlke AL, Sinha A, Sankowski R, Schick M, Lewis R, Dokalis N, Seubert B, Höchst B, Inverso D, Heide D, Zhang W, Weihrich P, Manske K, Wohlleber D, Anton M, Hoellein A, Seleznik G, Bremer J, Bleul S, Augustin HG, Scherer F, Koedel U, Weber A, Protzer U, Förster R, Wirth T, Aguzzi A, Meissner F, Prinz M, Baumann B, Höpken UE, Knolle

PA, von Baumgarten L, Keller U, Heikenwalder M. Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. *Cancer Cell*. 2019 Sep 16;36(3):250-267.e9. doi: 10.1016/j.ccell.2019.08.001. PMID: 31526758.

8. Scherger AK, Al-Maarri M, Maurer HC, Schick M, Maurer S, Öllinger R, Gonzalez-Menendez I, Martella M, Thaler M, Pechloff K, Steiger K, Sander S, Ruland J, Rad R, Quintanilla-Martinez L, Wunderlich FT, Rose-John S, Keller U. Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. *JCI Insight*. 2019 Aug 8;4(15):e128435. doi: 10.1172/jci.insight.128435. PMID: 31391340; PMCID: PMC6693839.
9. Maurer S, Herhaus P, Lippenmeyer R, Hänscheid H, Kircher M, Schirbel A, Maurer HC, Buck AK, Wester HJ, Einsele H, Grigoleit GU, Keller U, Lapa C. Side Effects of CXCR4-Targeted Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. *J Nucl Med*. 2019 Oct;60(10):1399-1405. doi: 10.2967/jnumed.118.223420. Epub 2019 Mar 8. PMID: 30850502; PMCID: PMC6785788.
10. Vag T, Steiger K, Rossmann A, Keller U, Noske A, Herhaus P, Ettl J, Niemeyer M, Wester HJ, Schwaiger M. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. *EJNMMI Res*. 2018 Sep 6;8(1):90. doi: 10.1186/s13550-018-0442-0. PMID: 30191351; PMCID: PMC6127070.
11. Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, Keller U, Lapa C. CXCR4-directed theranostics in oncology and inflammation. *Ann Nucl Med*. 2018 Oct;32(8):503-511. doi: 10.1007/s12149-018-1290-8. Epub 2018 Aug 13. PMID: 30105558; PMCID: PMC6182637.
12. Habringer S, Lapa C, Herhaus P, Schottelius M, Istvanffy R, Steiger K, Slotta-Huspenina J, Schirbel A, Hänscheid H, Kircher S, Buck AK, Götze K, Vick B, Jeremias I, Schwaiger M, Peschel C, Oostendorp R, Wester HJ, Grigoleit GU, Keller U. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. *Theranostics*. 2018 Jan 1;8(2):369-383. doi: 10.7150/thno.21397. PMID: 29290814; PMCID: PMC5743554.
13. Kurup S, McAllister B, Liskova P, Mistry T, Fanizza A, Stanford D, Slawska J, Keller U, Hoellein A. Design, synthesis and biological activity of N⁴-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase. *J Enzyme Inhib Med Chem*. 2018 Dec;33(1):74-84. doi: 10.1080/14756366.2017.1376666. PMID: 29115879; PMCID: PMC6009956.
14. Jacobs L, Habringer S, Slawska J, Huber K, Hauf E, Li Z, Refaeli Y, Schwaiger M, Rudelius M, Walch A, Keller U. Functional imaging in combination with mutation status

aids prediction of response to inhibiting B-cell receptor signaling in lymphoma. *Oncotarget*. 2017 Aug 24;8(45):78917-78929. doi: 10.18632/oncotarget.20551. PMID: 29108275; PMCID: PMC5668008.

15. Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Schirbel A, Buck AK, Kropf S, Schwaiger M, Keller U, Lassmann M, Wester HJ. [¹⁷⁷Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent. *Theranostics*. 2017 Jun 11;7(9):2350-2362. doi: 10.7150/thno.19119. PMID: 28744319; PMCID: PMC5525741.
16. Herhaus P, Habringer S, Vag T, Steiger K, Slotta-Huspenina J, Gerngroß C, Wiestler B, Wester HJ, Schwaiger M, Keller U. Response assessment with the CXCR4-directed positron emission tomography tracer [⁶⁸Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. *EJNMMI Res*. 2017 Dec;7(1):51. doi: 10.1186/s13550-017-0294-z. Epub 2017 Jun 2. PMID: 28577295; PMCID: PMC5457373.
17. Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, Targosz BS, Loewecke F, Gloeckner CJ, Ueffing M, Fulda S, Pfreundschuh M, Trümper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F. USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma. *EMBO Mol Med*. 2016 Aug 1;8(8):851-62. doi: 10.15252/emmm.201506047. PMID: 27317434; PMCID: PMC4967940.
18. Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. *Nat Med*. 2016 Jul;22(7):735-43. doi: 10.1038/nm.4128. Epub 2016 Jun 13. PMID: 27294876.
19. Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. *Haematologica*. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. Epub 2016 May 12. PMID: 27175029; PMCID: PMC4967572.
20. Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, Ettl J, Keller U, Wester HJ, Schwaiger M. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers. *J Nucl Med*. 2016

May;57(5):741-6. doi: 10.2967/jnumed.115.161034. Epub 2016 Jan 14. PMID: 26769866.

21. Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, Lückerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck AK, Einsele H, Wester HJ, Knop S. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with ¹⁷⁷Lu- and ⁹⁰Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. *J Nucl Med*. 2016 Feb;57(2):248-51. doi: 10.2967/jnumed.115.167361. Epub 2015 Nov 12. PMID: 26564323.
22. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Šimeček J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. *Theranostics*. 2015 Mar 1;5(6):618-30. doi: 10.7150/thno.11251. PMID: 25825601; PMCID: PMC4377730.
23. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. *EMBO Mol Med*. 2015 Apr;7(4):477-87. doi: 10.15252/emmm.201404698. PMID: 25736399; PMCID: PMC4403048.
24. Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe ⁶⁸Ga-pentixafor. *J Nucl Med*. 2015 Mar;56(3):410-6. doi: 10.2967/jnumed.114.151647. Epub 2015 Feb 19. PMID: 25698782.
25. Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F. Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. *Nat Med*. 2014 Dec;20(12):1401-9. doi: 10.1038/nm.3740. Epub 2014 Nov 24. PMID: 25419709.
26. Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Suprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U. GP130 activation induces myeloma and collaborates with MYC. *J Clin Invest*. 2014 Dec;124(12):5263-74. doi: 10.1172/JCI69094. Epub 2014 Nov 10. PMID: 25384216; PMCID: PMC4348946.

27. Huber K, Feuchtinger A, Borgmann DM, Li Z, Aichler M, Hauck SM, Zitzelsberger H, Schwaiger M, Keller U, Walch A. Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues. *Anal Chem*. 2014 Nov 4;86(21):10568-75. doi: 10.1021/ac502177y. Epub 2014 Oct 15. PMID: 25263480.
28. Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma. *Blood*. 2014 Sep 25;124(13):2081-90. doi: 10.1182/blood-2014-06-584524. Epub 2014 Aug 20. PMID: 25143484; PMCID: PMC4186537.
29. Herrmann K, Buck AK, Schuster T, Abbrederis K, Blümel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, Dechow T, Keller U. Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL. *Oncotarget*. 2014 Jun 30;5(12):4050-9. doi: 10.18632/oncotarget.1990. PMID: 24979177; PMCID: PMC4147305.
30. Graf N, Li Z, Herrmann K, Weh D, Aichler M, Slawska J, Walch A, Peschel C, Schwaiger M, Buck AK, Dechow T, Keller U. Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma. *Onco Targets Ther*. 2014 May 23;7:789-98. doi: 10.2147/OTT.S59314. PMID: 24920919; PMCID: PMC4043809.
31. Engel K, Rudelius M, Meinel FG, Peschel C, Keller U. An adult patient with Nijmegen Breakage Syndrome and Hodgkin's Lymphoma. *BMC Hematol*. 2014 Jan 16;14(1):2. doi: 10.1186/2052-1839-14-2. PMID: 24428841; PMCID: PMC3898043.
32. Dörr JR, Yu Y, Milanovic M, Beuster G, Zasada C, Däbritz JH, Lisec J, Lenze D, Gerhardt A, Schleicher K, Kratzat S, Purfürst B, Walenta S, Mueller-Klieser W, Gräler M, Hummel M, Keller U, Buck AK, Dörken B, Willmitzer L, Reimann M, Kempa S, Lee S, Schmitt CA. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. *Nature*. 2013 Sep 19;501(7467):421-5. doi: 10.1038/nature12437. Epub 2013 Aug 14. PMID: 23945590.
33. Graf N, Herrmann K, Numberger B, Zwisler D, Aichler M, Feuchtinger A, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, Peschel C, Schwaiger M, Keller U, Dechow T, Buck AK. [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner. *Eur J Nucl Med Mol Imaging*. 2013 Jan;40(1):34-43. doi: 10.1007/s00259-012-2255-0. Epub 2012 Oct 5. PMID: 23053327.

34. Li Z, Graf N, Herrmann K, Jünger A, Aichler M, Feuchtinger A, Baumgart A, Walch A, Peschel C, Schwaiger M, Buck A, Keller U, Dechow T. FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy. *Cancer Res.* 2012 Oct 1;72(19):5014-24. doi: 10.1158/0008-5472.CAN-12-0635. Epub 2012 Aug 8. PMID: 22875026.

35. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, Scheuerer C, Peschel C, Schwaiger M, Dechow T, Keller U. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma. *J Nucl Med.* 2011 Dec;52(12):1898-902. doi: 10.2967/jnumed.111.094698. Epub 2011 Nov 7. PMID: 22065875.

36. Herrmann K, Buck AK, Schuster T, Junger A, Wieder HA, Graf N, Ringshausen I, Rudelius M, Wester HJ, Schwaiger M, Keller U, Dechow T. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. *J Nucl Med.* 2011 May;52(5):690-6. doi: 10.2967/jnumed.110.084566. Epub 2011 Apr 15. PMID: 21498532.

37. den Hollander J, Rimpi S, Doherty JR, Rudelius M, Buck A, Hoellein A, Kremer M, Graf N, Scheerer M, Hall MA, Goga A, von Bubnoff N, Duyster J, Peschel C, Cleveland JL, Nilsson JA, Keller U. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. *Blood.* 2010 Sep 2;116(9):1498-505. doi: 10.1182/blood-2009-11-251074. Epub 2010 Jun 2. PMID: 20519624; PMCID: PMC2938839.